ReviewClinical pharmacokinetics2023
Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.
Review in Clinical pharmacokinetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Research hotspots and trends in therapeutic drug monitoring of anticancer drugs: a 1990-2024 bibliometric analysis.Frontiers in oncology · 2026Pooled it
- Target Attainment and Clinical and Biochemical Parameters Associated with the Pharmacokinetics of 12 Tyrosine Kinase Inhibitors.Clinical pharmacokinetics · 2026Article
- Time-Dependent Bias and Prognostic Confounding in Exposure-Response Analysis of Targeted Therapies: Lessons from Sunitinib in Metastatic Renal Cancer.Clinical pharmacology and therapeutics · 2026Article
- HPLC-MS Quantification of Multiple Tyrosine Kinase Inhibitors in Patients with Solid Tumors: Method Validation and Clinical Application.Pharmaceutics · 2026Article
- Design characteristics of mass balance studies conducted for protein kinase inhibitors.Cancer chemotherapy and pharmacology · 2026Article
- Optimizing imatinib sampling strategies through a population approach: a crucial step to model-informed precision dosing validation for point-of-care therapeutic drug monitoring.BMC pharmacology & toxicology · 2026Article
- Pharmacophore-targeted fluorescence sensing of ibrutinibRSC advances · 2026Article
- The extensive erythrocyte-plasma partitioning of trametinib - implications for pharmacokinetic studies and therapeutic drug monitoring.Pharmacological reports : PR · 2026Article
- Therapeutic Drug Monitoring and Model-Informed Precision Dosing of Oral TKIs and PARP Inhibitors: A Practical Framework for Clinical Implementation.Clinical pharmacokinetics · 2026Review
- Simulation of Imatinib Pharmacokinetics in pregnant women with chronic myeloid leukemia in the third trimester.European journal of clinical pharmacology · 2026Article
- Ponatinib inhibits LCK and PI3K signaling and promotes CD8Nature communications · 2026Article
- Neurofibromatosis type 1-plexiform neurofibromas: Integrating treatment across pediatric and adult populations.Neuro-oncology · 2026Review
- Population pharmacokinetics of encorafenib and binimetinib in real-world patients with BRAFCancer chemotherapy and pharmacology · 2026Article
- Global regulatory variability in small-molecule inhibitor approvals: Differences in timelines, dosing, and pediatric indications across FDA, EMA, and PMDA.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Selpercatinib-induced renal tubular damage resulting in symptomatic hyponatremia and polyuria: a case report.Cancer chemotherapy and pharmacology · 2026Article
- Optimizing Flumatinib Therapy in Chinese Chronic-Phase Chronic Myeloid Leukemia Based on Therapeutic Drug Monitoring.Drug design, development and therapy · 2026Article
- Optimizing Treatment, Minimizing Risk: Therapeutic Drug Monitoring in Hematological Malignancies.Mediterranean journal of hematology and infectious diseases · 2026Article
- Diagnostic challenge of systemic amyloidosis mimicking EGFR-TKI toxicity in lung adenocarcinoma: a case report.Translational lung cancer research · 2025Article
- Therapeutic Drug Monitoring of Oral Targeted Anticancer Drugs: Achievements, Experiences, Challenges, and the Path Forward.Therapeutic drug monitoring · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although kinase inhibitors (KI) frequently portray large interpatient variability, a 'one size fits all' regimen is still often used. In the meantime, relationships between exposure-response and exposure-toxicity have been established for several KIs, so this regimen could lead to unnecessary toxicity and suboptimal efficacy. Dose adjustments based on measured systemic pharmacokinetic levels-i.e., therapeutic drug monitoring (TDM)-could therefore improve treatment efficacy and reduce the incidence of toxicities. Therefore, the aim of this comprehensive review is to give an overview of the available evidence for TDM for the 77 FDA/EMA kinase inhibitors currently approved (as of July 1st, 2023) used in hematology and oncology. We elaborate on exposure-response and exposure-toxicity relationships for these kinase inhibitors and provide practical recommendations for TDM and discuss corresponding pharmacokinetic targets when possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.